Guangdong Zhongsheng Pharmaceutical (002317.SZ): The first participant has been enrolled in the Phase II clinical trial of Angladivir granules.
Zhongsheng Pharmaceutical (002317.SZ) issued an announcement that the company's controlling subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd...
Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), has successfully completed the first participant enrollment and dosing in the Phase II clinical trial of a class of innovative drug called Angladawir granules (research code: ZSP1273 granules) for the treatment of patients aged 2 to 17 with uncomplicated influenza A.
Related Articles

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


